Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators
Forest agreed to pay $50 million upfront for rights to several compounds in a novel class of drugs, including a lead drug that is Phase II-ready.
Forest agreed to pay $50 million upfront for rights to several compounds in a novel class of drugs, including a lead drug that is Phase II-ready.